Ra Pharmaceuticals Inc (RARX) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Ra Pharmaceuticals Inc (Ra Pharmaceuticals) is a clinical stage biopharmaceutical company that develops therapeutics for the treatment of diseases caused due to uncontrolled activation of the complement system. Ra Pharmaceuticals develops its pipeline products through its proprietary peptide chemistry platform. Its lead product candidate, RA101495 is a self-administered subcutaneous (SC) injection into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Ra Pharmaceuticals pipeline also includes RA101495, an administered SC, to treat debilitating complement-mediated diseases such as atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG) and lupus nephritis (LN). The company also carries out various preclinical programs intended for the treatment of orphan renal diseases, ocular, autoimmune and CNS diseases; and a non-complement cardiovascular product candidate. Ra Pharmaceuticals is headquartered on Cambridge, Massachusetts, the US.

Ra Pharmaceuticals Inc (RARX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 4
List of Figures 4
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Ra Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Ra Pharma Raises USD58.5 Million in Series B Financing 11
Ra Pharma Raises US$8.6 Million In Second Tranche Of Series A Financing 13
Licensing Agreements 14
Merck Enters into Licensing Agreement with Ra Pharma 14
Equity Offering 16
Ra Pharma Plans to Raise up to USD50 Million in Public Offering of Shares 16
Ra Pharma Prices Public Offering of Shares for USD50.4 Million 17
Ra Pharma Prices IPO for USD91 Million 19
Ra Pharmaceuticals Inc - Key Competitors 21
Ra Pharmaceuticals Inc - Key Employees 22
Ra Pharmaceuticals Inc - Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Financial Announcements 24
May 09, 2018: Ra Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update 24
Mar 14, 2018: Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 26
Nov 09, 2017: Ra Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update 28
Aug 09, 2017: Ra Pharmaceuticals Reports Second Quarter 2017 Financial Results 29
May 11, 2017: Ra Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update 31
Mar 06, 2017: Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 32
Corporate Communications 34
Apr 18, 2018: Ra Pharmaceuticals Names John C. King as Chief Commercial Officer 34
Government and Public Interest 35
Jul 18, 2017: OMRF researcher tests new approach for treating deadly blood infection 35
Clinical Trials 36
Jul 19, 2017: Ra Pharmaceuticals Announces Publication of Positive Preclinical Data with RA101295 for the Treatment of Escherichia Coli Sepsis 36
Apr 26, 2017: Ra Pharmaceuticals Initiates Dosing of RA101495 in PNH Patients 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List Of Tables

List of Tables
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ra Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Ra Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Ra Pharma Raises USD58.5 Million in Series B Financing 11
Ra Pharma Raises US$8.6 Million In Second Tranche Of Series A Financing 13
Merck Enters into Licensing Agreement with Ra Pharma 14
Ra Pharma Plans to Raise up to USD50 Million in Public Offering of Shares 16
Ra Pharma Prices Public Offering of Shares for USD50.4 Million 17
Ra Pharma Prices IPO for USD91 Million 19
Ra Pharmaceuticals Inc, Key Competitors 21
Ra Pharmaceuticals Inc, Key Employees 22

List Of Figures

List of Figures
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Ra Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9

Juno Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Juno Therapeutics Inc (Juno) is a clinical-stage company that develops novel cellular immunotherapies. The company formulates cell-based cancer immunotherapies based on platforms such as chimeric antigen receptor and high-affinity T

USD 250 View Report

Aquestive Therapeutics Inc (AQST) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Aquestive Therapeutics Inc (Aquestive Therapeutics) is a pharmaceutical company that discovers, develops and commercializes prescription drug products and a pipeline of prescription formulations. The company offers PharmFilm a drug delivery

USD 250 View Report

Constellation Pharmaceuticals Inc (CNST) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Constellation Pharmaceuticals Inc (Constellation) is a clinical biopharmaceutical company that focuses to develop novel therapeutics for the treatment of serious unmet medical needs in patients with cancers associated with abnormal

USD 250 View Report

Cannabics Pharmaceuticals Inc (CNBX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Cannabics Pharmaceuticals Inc (Cannabics Pharmaceuticals), formerly Thrust Energy Corp, is a drug development company that develops cannabinoid-based therapies for cancer. The company develops High Content Screening (HCS) Platform, an automated

USD 250 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available